Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2022

View Archived Issues

CD14 associated with poor cognitive function in survivors of testicular germ-cell tumors

Lipidated IL-22 ameliorates colon inflammation in preclinical colitis model

Study shows how gut-derived metabolites enter the brain and affect behavior

IBD-3540, a novel gut-restricted GCPII inhibitor with oral preclinical activity in models of colitis

Shaanxi Synthetic Pharmaceutical divulges new antiarthritic drugs

Guangzhou Henovcom Bioscience discloses new antivirals

T2YC presents new integrin modulators

IFM Due synthesizes new hSTING antagonists

Institute of Medicinal Biotechnology presents new androgen receptor antagonists

Targeting of CRYAB with 25-hydroxycholesterol induces kills senescent cells in vitro and in vivo

AU-011 shows promising binding and tumor distribution in models of urothelial neoplasia

DNA methylation mediated by METTL3-METTL14 complex is largely restricted by structured RNA elements

CD70 identified as promising therapeutic target in advanced RCC

Moderna announces new mRNA vaccine candidates for HSV, VZV and cancer

SIGMAR1 targeting ameliorates preclinical Wolfram syndrome symptoms

GR-3027 reverses neuroinflammation in rat model of hyperammonemia

"Twin study" of sorts brings insight into arthritis microbiome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...